← Leaderboards
Isabelle Audo
Columbia University Health Sciences
$3,637,126
Attributed
$10,911,378
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2020–24$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,911,378 · 1
By mechanism
R24$10,911,378 · 1
Top collaborators
- Janet R. Sparrow5 shared
- Stephen H Tsang5 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Janet R. Sparrow$21,221,236
- Gunnar Hargus$1,575,180
- Livio Pellizzoni$13,515,447
- Nicholas David Nolan$146,206
- Karen S Marder$15,291,810
Others in their field
Other Emerging Leaders on “Genetic Analysis”
- Yunda Huang · Fred Hutchinson Cancer Center$52,276,533
- Leonard Freedman · Leidos Biomedical Research, Inc.$47,509,521
- Evan Z Macosko · Broad Institute, Inc.$28,857,317
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Lynn Briscoe · Leidos Biomedical Research, Inc.$24,621,503
- Chani Eduard · Precision Bioservices, Inc.$19,909,203
Research focus
Genetic AnalysisGenesGene Therapy TrialAllelesAutosomal Dominant MutationAdolescentGenerationsCellsChloridesChromosomesClinicClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsCostCrispr/Cas TechnologyAffectCustomDesignDisease ProgressionDrug KineticsEngineeringFda ApprovedGain Of FunctionGenome
Grant awards (5)
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,153,230
R24 · FY2024 · EY
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,178,277
R24 · FY2023 · EY
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,189,617
R24 · FY2022 · EY
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,189,617
R24 · FY2021 · EY
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,200,637
R24 · FY2020 · EY